| Towards a proteome-scale map of the human protein–protein interaction network JF Rual, K Venkatesan, T Hao, T Hirozane-Kishikawa, A Dricot, N Li, ... Nature 437 (7062), 1173-1178, 2005 | 3527 | 2005 |
| Judging the quality of gene expression-based clustering methods using gene annotation FD Gibbons, FP Roth Genome research 12 (10), 1574-1581, 2002 | 439 | 2002 |
| Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ... Nature communications 9 (1), 5341, 2018 | 434 | 2018 |
| Intensity-based protein identification by machine learning from a library of tandem mass spectra JE Elias, FD Gibbons, OD King, FP Roth, SP Gygi Nature biotechnology 22 (2), 214-219, 2004 | 388 | 2004 |
| A critical assessment of Mus musculusgene function prediction using integrated genomic evidence L Peña-Castillo, M Tasan, CL Myers, H Lee, T Joshi, C Zhang, Y Guan, ... Genome biology 9, 1-19, 2008 | 298 | 2008 |
| Predicting protein complex membership using probabilistic network reliability S Asthana, OD King, FD Gibbons, FP Roth Genome research 14 (6), 1170-1175, 2004 | 269 | 2004 |
| AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia EK Keeton, K McEachern, KS Dillman, S Palakurthi, Y Cao, MR Grondine, ... Blood, The Journal of the American Society of Hematology 123 (6), 905-913, 2014 | 260 | 2014 |
| Combining guilt-by-association and guilt-by-profiling to predict Saccharomyces cerevisiaegene function W Tian, LV Zhang, M Taşan, FD Gibbons, OD King, J Park, Z Wunderlich, ... Genome biology 9, 1-21, 2008 | 112 | 2008 |
| Genomewide Identification of Sko1 Target Promoters Reveals a Regulatory Network That Operates in Response to Osmotic Stress in Saccharomyces cerevisiae M Proft, FD Gibbons, M Copeland, FP Roth, K Struhl Eukaryotic Cell 4 (8), 1343-1352, 2005 | 90 | 2005 |
| Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy CM Patterson, SB Balachander, I Grant, P Pop-Damkov, B Kelly, ... Communications Biology 4 (1), 112, 2021 | 71 | 2021 |
| Chipper: discovering transcription-factor targets from chromatin immunoprecipitation microarrays using variance stabilization FD Gibbons, M Proft, K Struhl, FP Roth Genome biology 6, 1-9, 2005 | 68 | 2005 |
| Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of nonsmall cell lung cancer … RA Ward, MJ Anderton, P Bethel, J Breed, C Cook, EJ Davies, A Dobson, ... Journal of medicinal chemistry 62 (24), 11004-11018, 2019 | 47 | 2019 |
| AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ... Clinical Cancer Research 26 (24), 6535-6549, 2020 | 46 | 2020 |
| An en masse phenotype and function prediction system for Mus musculus M Taşan, W Tian, DP Hill, FD Gibbons, JA Blake, FP Roth Genome biology 9, 1-16, 2008 | 33 | 2008 |
| SILVER helps assign peptides to tandem mass spectra using intensity-based scoring FD Gibbons, JE Elias, SP Gygi, FP Roth Journal of the American Society for Mass Spectrometry 15, 910-912, 2004 | 28 | 2004 |
| Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response B Schoeberl, B Harms, FD Gibbons, JB Fitzgerald, MD Onsum, U Nielsen, ... US Patent App. 12/707,521, 2011 | 26 | 2011 |
| FuncBase: a resource for quantitative gene function annotation JE Beaver, M Taşan, FD Gibbons, W Tian, TR Hughes, FP Roth Bioinformatics 26 (14), 1806-1807, 2010 | 18 | 2010 |
| Mixture dynamics: combination therapy in oncology J Gabrielsson, FD Gibbons, LA Peletier European Journal of Pharmaceutical Sciences 88, 132-146, 2016 | 16 | 2016 |
| MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells … A Huhalov, S Adams, V Paragas, S Oyama, R Overland, L Luus, ... Cancer Research 70 (8_Supplement), 3485-3485, 2010 | 16 | 2010 |
| AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021 | 15 | 2021 |
Frederick P (Fritz) RothUniversity of Pittsburgh School of Medicine, Department of Computational & Systems BiologyVerified email at pitt.edu
